Oncternal Therapeutics, Inc. — key financial figures for fiscal year 2023 (in USD), standardized from XBRL/iXBRL filings by Hub-Equity:

Revenue (FY2023)

$785.0K

Net Income/Loss (FY2023)

-$39.5M

Total Assets (FY2023)

$36.7M

Total Equity (FY2023)

$30.1M

Cash Flows from Operating Activities (FY2023)

-$32.2M

Source: Oncternal Therapeutics, Inc. 10-K filing (FY2023). Full income statement, balance sheet and cash flow, restatement-aware and traceable to the source filing, at Hub-Equity.